% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Ballhausen:277755,
      author       = {A. Ballhausen and M. Karthaus and S. Fruehauf and U.
                      Graeven and L. Müller and A. O. König and L. F. von
                      Weikersthal and G. Sommerhäuser and A. H. S. Alig and E.
                      Goekkurt and J. W. Meyer-Knees and A. Kurreck and A. Stahler
                      and S. Held and S. Kasper and K. Heinrich and V.
                      Heinemann$^*$ and S. Stintzing$^*$ and T. Trarbach and D. P.
                      Modest$^*$},
      title        = {{H}ealth-related quality of life in patients with {RAS}
                      wild-type metastatic colorectal cancer treated with
                      fluorouracil and folinic acid with or without panitumumab as
                      maintenance therapy: a prespecified secondary analysis of
                      the {P}ana{M}a ({AIO} {KRK} 0212) trial.},
      journal      = {European journal of cancer},
      volume       = {190},
      issn         = {0014-2964},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2023-01472},
      pages        = {112955},
      year         = {2023},
      abstract     = {The PanaMa trial demonstrated significant benefit in
                      progression-free survival with the addition of panitumumab
                      (Pmab) to fluorouracil and folinic acid (FU/FA) as
                      maintenance therapy following first-line induction therapy
                      with FOLFOX/Pmab in patients with RAS wild-type metastatic
                      colorectal cancer. Here, we report health-related quality of
                      life (HRQOL) analyses from the PanaMa trial.HRQOL outcomes
                      were evaluated using European Organisation for Research and
                      Treatment of Cancer Quality of Life Questionnaire Core 30
                      (EORTC QLQ-C30) at every cycle of therapy until disease
                      progression/death. HRQOL outcomes were mean and individual
                      changes in EORTC QLQ-C30 from baselines (before induction
                      therapy and before maintenance therapy) to each cycle of
                      treatment. Comparative analyses were performed by
                      randomisation status and treatment arm for induction- and
                      maintenance-therapy, respectively. The trial is registered
                      with clinicaltrials.gov (NCT01991873).At least one HRQOL
                      questionnaire was completed by a total of 349/377 $(93\%)$
                      patients who received induction therapy, and by 237/248
                      $(96\%)$ patients who were randomised and received
                      maintenance therapy. During induction therapy, most HRQOL
                      dimensions remained stable or showed improvement, while
                      appetite loss and diarrhoea significantly deteriorated.
                      During maintenance therapy, HRQOL dimensions remained
                      stable, while those that deteriorated during induction
                      therapy showed significant improvement, without significant
                      differences between the treatment arms.Maintenance therapy
                      improves HRQOL dimensions that initially deteriorated during
                      induction therapy while stabilising HRQOL in other
                      dimensions. The addition of Pmab to FU/FA as maintenance
                      therapy in patients with RAS wild-type metastatic colorectal
                      cancer prolongs progression-free survival without negative
                      impact on HRQOL.},
      keywords     = {Anti-EGFR therapy (Other) / First-line treatment (Other) /
                      Health-related quality of life (Other) / Metastatic
                      colorectal cancer (Other) / Patient-reported outcomes
                      (Other) / RAS wild-type (Other)},
      cin          = {MU01 / BE01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331 / I:(DE-He78)BE01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37454537},
      doi          = {10.1016/j.ejca.2023.112955},
      url          = {https://inrepo02.dkfz.de/record/277755},
}